HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination
with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid
tumors.